Takano M, Ikeda Y, Kudoh K, Kita T, Sasaki N, Kikuchi Y
Department of Obstetrics and Gynecology, National Defense Medical College, Tokorozawa, Saitama, Japan.
Eur J Gynaecol Oncol. 2013;34(1):90-3.
A combination therapy with gemcitabine and oxaliplatin (GEMOX) yielded a moderate activity in platinum-resistant ovarian cancers; however, frequent severe toxicities, such as thrombocytopenia and neurotoxicity, were observed. A certain modification of schedule might therefore facilitate the clinical application of the regimen. The authors report two cases that achieved complete response to a weekly administration of bevacizumab and GEMOX.
Two patients with platinum-resistant recurrent ovarian cancers received a weekly regimen of GEMOX with bevacizumab: 2 mg/kg of bevacizumab, 300 mg/m2 of gemcitabine, and 30 mg/m2 of oxaliplatin, three weeks on and one week off, Q4 weeks. Complete remission was observed after three to four courses of therapy. Hematologic and non-hematologic toxicities more than grade 2 were not observed during chemotherapy. The patients are now without tumor progression more than 12 months after initiation of therapy.
Weekly administration of bevacizumab and GEMOX had potential activity in recurrent and refractory ovarian carcinomas. These findings warrant necessity of further trial in such clinical settings.
吉西他滨与奥沙利铂联合治疗（GEMOX）在铂耐药性卵巢癌中显示出一定活性；然而，观察到频繁出现严重毒性，如血小板减少和神经毒性。因此，对治疗方案进行某些调整可能会促进该方案的临床应用。作者报告了两例对每周一次的贝伐单抗联合GEMOX治疗实现完全缓解的病例。
两名铂耐药性复发性卵巢癌患者接受了每周一次的GEMOX联合贝伐单抗治疗方案：贝伐单抗2 mg/kg、吉西他滨300 mg/m²、奥沙利铂30 mg/m²，每三周给药一次，休息一周，每四周重复。在三到四个疗程的治疗后观察到完全缓解。化疗期间未观察到2级以上的血液学和非血液学毒性。患者在开始治疗后12个月以上无肿瘤进展。
每周一次的贝伐单抗联合GEMOX治疗对复发性和难治性卵巢癌具有潜在活性。这些发现证明有必要在这种临床环境中进行进一步试验。
